The Centers for Medicare & Medicaid Services Friday finalized policy and technical changes to the Medicare Advantage and prescription drug benefit for contract year 2023. To improve MA plan oversight, the final rule would reinstate plan reporting on medical loss ratio requirements that were relaxed in 2017; require plans to demonstrate a sufficient provider network when applying for a new or expanded contract; strengthen CMS’s ability to evaluate plan performance when reviewing proposals for new or expanded contracts; require plans to provide certain materials to beneficiaries in culturally and linguistically appropriate ways; and strengthen oversight of third-party marketing organizations, among other consumer protection provisions. The rule also codifies provisions intended to improve and better assess quality for special needs plans that serve beneficiaries dually eligible for Medicare and Medicaid. 

Blog
Public
Medicare Advantage now covers more than half of eligible Medicare beneficiaries, making its impact on hospitals, health systems and patients impossible to…
Headline
The Medicare Payment Advisory Commission June 15 released its June report to Congress that estimated the association between Medicare Advantage enrollment and…
Headline
The Department of Health and Human Services Office of Inspector General June 11 released two reports on high rates of coverage denials by Medicare Advantage…
Headline
Members of Congress and hospital and health system leaders today gathered for a briefing in Washington, D.C., to discuss how payment delays in Medicare…
Headline
The Centers for Medicare & Medicaid Services May 28 issued a final rule making changes to the Increasing Organ Transplant Access Model beginning July 1.…
Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…